18Fluorine sodium fluoride positron emission tomography, a potential biomarker of transthyretin cardiac amyloidosis

Authors

Rachelle Morgenstern
Randy Yeh
Adam Castano
Mathew S Maurer
Sabahat Bokhari

Publication/Presentation Date

10-1-2018

Abstract

BACKGROUND: Non-invasive imaging to diagnose and quantify amyloid load, progression, and response to treatment are central for the care of patients with cardiac amyloidosis.

METHODS: Patients with biopsy-proven transthyretin (ATTR-CA) and light-chain cardiac amyloidosis (AL) (3 ATTRwt, 2 ATTRV122I, 2 AL) and controls (n = 5), underwent

RESULTS: Qualitative

CONCLUSION:

Volume

25

Issue

5

First Page

1559

Last Page

1567

ISSN

1532-6551

Published In/Presented At

Morgenstern, Rachelle et al. “18Fluorine sodium fluoride positron emission tomography, a potential biomarker of transthyretin cardiac amyloidosis.” Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology vol. 25,5 (2018): 1559-1567. doi:10.1007/s12350-017-0799-x

Disciplines

Medicine and Health Sciences

PubMedID

28176254

Department(s)

Department of Medicine

Document Type

Article